Glatiramer acetate attenuates the pro-migratory profile of adhesion molecules on various immune cell subsets in multiple sclerosis

Clinical and Experimental Immunology

Volumn 173, Issue 3, 2013, Pages 381-389

  Sellner, J ^a,b   Koczi, W ^a   Harrer, A ^a   Oppermann, K ^a   Obregon Castrillo, E ^a   Pilz, G ^a   Wipfler, P ^a   Afazel, S ^a   Haschke Becher, E ^a   Trinka, E ^a   Kraus, J ^a  

^a PARACELSUS MEDICAL UNIVERSITY   (Austria)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Adhesion molecule; Glatiramer acetate; Immunomodulation; Multiple sclerosis; Transmigration

Indexed keywords

CD31 ANTIGEN; CELL ADHESION MOLECULE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; GLATIRAMER; INTERCELLULAR ADHESION MOLECULE 1; INTERCELLULAR ADHESION MOLECULE 3; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; PADGEM PROTEIN; VASCULAR CELL ADHESION MOLECULE 1; VERY LATE ACTIVATION ANTIGEN; VERY LATE ACTIVATION ANTIGEN 4;

ADULT; ARTICLE; B LYMPHOCYTE; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL SURFACE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOFLUORESCENCE TEST; LYMPHOCYTE SUBPOPULATION; MALE; MONOCYTE; MULTIPLE SCLEROSIS; NATURAL KILLER CELL; NATURAL KILLER T CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; UPREGULATION;

ADHESION MOLECULE; GLATIRAMER-ACETATE; IMMUNOMODULATION; MULTIPLE SCLEROSIS; TRANSMIGRATION;

ADULT; CASE-CONTROL STUDIES; CELL ADHESION MOLECULES; CELL MEMBRANE; CELL MOVEMENT; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PEPTIDES;

EID: 84881528121     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12125     Document Type: Article

References (47)

1. Sellner J, Kraus J, Awad A, Milo R, Hemmer B, Stüve O. The increasing incidence and prevalence of female multiple sclerosis-a critical analysis of potential environmental factors. Autoimmun Rev 2011; 10:495-502.
2. Korn T. Pathophysiology of multiple sclerosis. J Neurol 2008; 255 (Suppl. 6):2-6.
3. Stadelmann C, Wegner C, Bruck W. Inflammation, demyelination, and degeneration-recent insights from MS pathology. Biochim Biophys Acta 2011; 1812:275-282.
4. Mikol DD, Barkhof F, Chang P etal. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Lancet Neurol 2008; 7:903-914.
5. Mancardi GL, Sardanelli F, Parodi RC etal. Effect of copolymer-1 on serial gadolinium-enhanced MRI in relapsing remitting multiple sclerosis. Neurology 1998; 50:1127-1133.
6. Sormani MP, Bruzzi P, Comi G, Filippi M. The distribution of the magnetic resonance imaging response to glatiramer acetate in multiple sclerosis. Mult Scler 2005; 11:447-449.
7. Kala M, Miravalle A, Vollmer T. Recent insights into the mechanism of action of glatiramer acetate. J Neuroimmunol 2011; 235:9-17.
8. Hyun YM, Lefort CT, Kim M. Leukocyte integrins and their ligand interactions. Immunol Res 2009; 45:195-208.
9. Bo L, Peterson JW, Mork S etal. Distribution of immunoglobulin superfamily members ICAM-1, -2, -3, and the beta 2 integrin LFA-1 in multiple sclerosis lesions. J Neuropathol Exp Neurol 1996; 55:1060-1072.
10. Elovaara I, Ukkonen M, Leppakynnas M etal. Adhesion molecules in multiple sclerosis: relation to subtypes of disease and methylprednisolone therapy. Arch Neurol 2000; 57:546-551.
11. Prat A, Al-Asmi A, Duquette P, Antel JP. Lymphocyte migration and multiple sclerosis: relation with disease course and therapy. Ann Neurol 1999; 46:253-256.
12. Kim HJ, Biernacki K, Prat A, Antel JP, Bar-Or A. Inflammatory potential and migratory capacities across human brain endothelial cells of distinct glatiramer acetate-reactive T cells generated in treated multiple sclerosis patients. Clin Immunol 2004; 111:38-46.
13. Simoni Y, Diana J, Ghazarian L, Beaudoin L, Lehuen A. Therapeutic manipulation of natural killer (NK) T cells in autoimmunity: are we close to reality? Clin Exp Immunol 2013; 171:8-19.
14. Hamann I, Dorr J, Glumm R etal. Characterization of natural killer cells in paired CSF and blood samples during neuroinflammation. J Neuroimmunol 2013; 254:165-169.
15. Rieckmann P, Altenhofen B, Riegel A, Baudewig J, Felgenhauer K. Soluble adhesion molecules (sVCAM-1 and sICAM-1) in cerebrospinal fluid and serum correlate with MRI activity in multiple sclerosis. Ann Neurol 1997; 41:326-333.
16. Giovannoni G, Lai M, Thorpe J etal. Longitudinal study of soluble adhesion molecules in multiple sclerosis: correlation with gadolinium enhanced magnetic resonance imaging. Neurology 1997; 48:1557-1565.
17. Kuenz B, Lutterotti A, Khalil M etal. Plasma levels of soluble adhesion molecules sPECAM-1, sP-selectin and sE-selectin are associated with relapsing-remitting disease course of multiple sclerosis. J Neuroimmunol 2005; 167:143-149.
18. Polman CH, Reingold SC, Edan G etal. Diagnostic criteria for multiple sclerosis: 2005 revisions to the 'McDonald Criteria'. Ann Neurol 2005; 58:840-846.
19. Harrer A, Wipfler P, Einhaeupl M etal. Natalizumab therapy decreases surface expression of both VLA-heterodimer subunits on peripheral blood mononuclear cells. J Neuroimmunol 2011; 234:148-154.
20. Kraus J, Oschmann P, Engelhardt B etal. Soluble and cell surface ICAM-1 as markers for disease activity in multiple sclerosis. Acta Neurol Scand 1998; 98:102-109.
21. Correale J, Bassani Molinas Mde L. Temporal variations of adhesion molecules and matrix metalloproteinases in the course of MS. J Neuroimmunol 2003; 140:198-209.
22. Jensen J, Krakauer M, Sellebjerg F. Cytokines and adhesion molecules in multiple sclerosis patients treated with interferon-beta1b. Cytokine 2005; 29:24-30.
23. Battistini L, Piccio L, Rossi B etal. CD8+ T cells from patients with acute multiple sclerosis display selective increase of adhesiveness in brain venules: a critical role for P-selectin glycoprotein ligand-1. Blood 2003; 101:4775-4782.
24. Raine CS. Multiple sclerosis: immune system molecule expression in the central nervous system. J Neuropathol Exp Neurol 1994; 53:328-337.
25. Rothhammer V, Heink S, Petermann F etal. Th17 lymphocytes traffic to the central nervous system independently of alpha4 integrin expression during EAE. J Exp Med 2011; 208:2465-2476.
26. Calabresi PA, Pelfrey CM, Tranquill LR, Maloni H, McFarland HF. VLA-4 expression on peripheral blood lymphocytes is downregulated after treatment of multiple sclerosis with interferon beta. Neurology 1997; 49:1111-1116.
27. Prat A, Biernacki K, Lavoie JF, Poirier J, Duquette P, Antel JP. Migration of multiple sclerosis lymphocytes through brain endothelium. Arch Neurol 2002; 59:391-397.
28. De Jager PL, Rossin E, Pyne S etal. Cytometric profiling in multiple sclerosis uncovers patient population structure and a reduction of CD8low cells. Brain 2008; 131:1701-1711.
29. Haas J, Bekeredjian-Ding I, Milkova M etal. B cells undergo unique compartmentalized redistribution in multiple sclerosis. J Autoimmun 2011; 37:289-299.
30. Kuenz B, Lutterotti A, Ehling R etal. Cerebrospinal fluid B cells correlate with early brain inflammation in multiple sclerosis. PLoS ONE 2008; 3:e2559.
31. Sellebjerg F, Bornsen L, Khademi M etal. Increased cerebrospinal fluid concentrations of the chemokine CXCL13 in active MS. Neurology 2009; 73:2003-2010.
32. Krumbholz M, Theil D, Cepok S etal. Chemokines in multiple sclerosis: CXCL12 and CXCL13 up-regulation is differentially linked to CNS immune cell recruitment. Brain 2006; 129:200-211.
33. Alter A, Duddy M, Hebert S etal. Determinants of human B cell migration across brain endothelial cells. J Immunol 2003; 170:4497-4505.
34. Niino M, Hirotani M, Miyazaki Y, Sasaki H. Memory and naive B cell subsets in patients with multiple sclerosis. Neurosci Lett 2009; 464:74-78.
35. Lee-Chang C, Top I, Zephir H etal. Primed status of transitional B cells associated with their presence in the cerebrospinal fluid in early phases of multiple sclerosis. Clin Immunol 2011; 139:12-20.
36. Uzawa A, Mori M, Masuda S, Kuwabara S. Markedly elevated soluble intercellular adhesion molecule 1, soluble vascular cell adhesion molecule 1 levels, and blood-brain barrier breakdown in neuromyelitis optica. Arch Neurol 2011; 68:913-917.
37. Millonig A, Hegen H, Di Pauli F etal. Natalizumab treatment reduces endothelial activity in MS patients. J Neuroimmunol 2010; 227:190-194.
38. Graber JJ, Dhib-Jalbut S. Biomarkers of disease activity in multiple sclerosis. J Neurol Sci 2011; 305:1-10.
39. Kraus J, Bauer R, Chatzimanolis N etal. Interferon-beta 1b leads to a short-term increase of soluble but long-term stabilisation of cell surface bound adhesion molecules in multiple sclerosis. J Neurol 2004; 251:464-472.
40. Niino M, Bodner C, Simard ML etal. Natalizumab effects on immune cell responses in multiple sclerosis. Ann Neurol 2006; 59:748-754.
41. Wipfler P, Oppermann K, Pilz G etal. Adhesion molecules are promising candidates to establish surrogate markers for natalizumab treatment. Mult Scler 2011; 17:16-23.
42. Kurosaki T. Paradox of B cell-targeted therapies. J Clin Invest 2008; 118:3260-3263.
43. Lalive PH, Neuhaus O, Benkhoucha M etal. Glatiramer acetate in the treatment of multiple sclerosis: emerging concepts regarding its mechanism of action. CNS Drugs 2011; 25:401-414.
44. Van Kaer L. Glatiramer acetate for treatment of MS: regulatory B cells join the cast of players. Exp Neurol 2011; 227:19-23.
45. Farina C, Weber MS, Meinl E, Wekerle H, Hohlfeld R. Glatiramer acetate in multiple sclerosis: update on potential mechanisms of action. Lancet Neurol 2005; 4:567-575.
46. Duda PW, Schmied MC, Cook SL, Krieger JI, Hafler DA. Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis. J Clin Invest 2000; 105:967-976.
47. Chen M, Conway K, Johnson KP, Martin R, Dhib-Jalbut S. Sustained immunological effects of Glatiramer acetate in patients with multiple sclerosis treated for over 6 years. J Neurol Sci 2002; 201:71-77.